Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 1
1995 8
1996 14
1997 12
1998 25
1999 33
2000 44
2001 38
2002 56
2003 48
2004 61
2005 75
2006 70
2007 70
2008 73
2009 76
2010 82
2011 72
2012 80
2013 95
2014 63
2015 55
2016 39
2017 42
2018 44
2019 37
2020 33
2021 27
2022 25
2023 19
2024 28
2025 24
2026 11

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,362 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial. Clear all
Page 1
Lamivudine therapy for chronic hepatitis B in children: a meta-analysis.
Luo A, Jiang X, Ren H. Luo A, et al. Virol J. 2019 Jul 4;16(1):88. doi: 10.1186/s12985-019-1193-x. Virol J. 2019. PMID: 31272463 Free PMC article.
BACKGROUND: Currently, there is no consensus on the effects and safety of lamivudine therapy for chronic hepatitis B (CHB) in children. METHOD: Both English and Chinese databases were searched comprehensively. An odds ratio (OR) and a standard mean difference (SMD) were us …
BACKGROUND: Currently, there is no consensus on the effects and safety of lamivudine therapy for chronic hepatitis B (CHB) in childre …
Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, Rockstroh J, Wei X, Custodio J, White K, Martin H, Cheng A, Quirk E. Gallant J, et al. Lancet. 2017 Nov 4;390(10107):2063-2072. doi: 10.1016/S0140-6736(17)32299-7. Epub 2017 Aug 31. Lancet. 2017. PMID: 28867497 Clinical Trial.
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and tenofovir alafenamide group and 93.0% of patients (n=293 of 315) in the dolutegravir, abacavir, and lamivudine group (difference -0.6%, …
At week 48, HIV-1 RNA less than 50 copies per mL was achieved in 92.4% of patients (n=290 of 314) in the bictegravir, emtricitabine, and ten …
Lamivudine and Entecavir for Acute Hepatitis B: A Systematic Review and Meta-Analysis.
Henriquez-Camacho C, Hijas-Gomez AI, Risco Risco C, Ruiz Lapuente MA, Escudero-Sanchez R, Cuerda VM. Henriquez-Camacho C, et al. Viruses. 2023 Nov 10;15(11):2241. doi: 10.3390/v15112241. Viruses. 2023. PMID: 38005918 Free PMC article.
The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to placebo or no intervention for treating acute primary HBV infection. ...Seroconversion of HBsAg to negative favored placebo/standard-of-care comp …
The purpose of this review was to determine the efficacy of nucleoside analogues (NA) (lamivudine versus entecavir) compared to place …
Efficacy of dolutegravir plus lamivudine in treatment-naive people living with HIV without baseline drug-resistance testing available (D2ARLING): 48-week results of a phase 4, randomised, open-label, non-inferiority trial.
Cordova E, Hernandez Rendon J, Mingrone V, Martin P, Arevalo Calderon G, Seleme S, Ballivian J, Porteiro N. Cordova E, et al. Lancet HIV. 2025 Feb;12(2):e95-e104. doi: 10.1016/S2352-3018(24)00294-7. Epub 2025 Jan 15. Lancet HIV. 2025. PMID: 39826566 Clinical Trial.
BACKGROUND: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without baseline resistance testing raises concerns about the potential presence of pretreatment lamivudine resistance. ...We randomly assigned (1 …
BACKGROUND: Dolutegravir plus lamivudine has emerged as a preferred treatment for HIV; however, initiating this regimen without basel …
Lamivudine's efficacy and safety in preventing mother-to-child transmission of hepatitis B: A meta-analysis.
Khalighinejad P, Alavian SM, Fesharaki MG, Jalilianhasanpour R. Khalighinejad P, et al. Turk J Gastroenterol. 2019 Jan;30(1):66-74. doi: 10.5152/tjg.2018.18148. Turk J Gastroenterol. 2019. PMID: 30475212 Free PMC article.
Studies were identified by searching various databases up to January 2016 for variations of the following phrase: "lamivudine AND (pregnancy or pregnant) AND (HBV or hepatitis)." Subjects who had received lamivudine were included in the case group, and those who had …
Studies were identified by searching various databases up to January 2016 for variations of the following phrase: "lamivudine AND (pr …
Lamivudine vs placebo or no treatment in preventing the transmission of hepatitis B virus during pregnancy: a systematic review and meta-analysis.
Zhao P, Qian X, Su C, Yang X, Bai X. Zhao P, et al. Trans R Soc Trop Med Hyg. 2020 Feb 7;114(2):121-130. doi: 10.1093/trstmh/trz078. Trans R Soc Trop Med Hyg. 2020. PMID: 31703121
Studies were included if they (1) were human RCT studies, (2) indicated exposure to lamivudine, (3) explicitly indicated control to placebo or no treatment, (4) indicated the participants were pregnant women infected with HBVand (5) compared the outcome of interest as the …
Studies were included if they (1) were human RCT studies, (2) indicated exposure to lamivudine, (3) explicitly indicated control to p …
Impact of lamivudine treatment in late pregnancy on the development of the foetal immune response to hepatitis B virus: a meta-analysis in R with the metafor package.
Zhao P, Zhao Y, Du M, Chen X, Lu Y. Zhao P, et al. Trans R Soc Trop Med Hyg. 2024 Apr 6;118(4):264-272. doi: 10.1093/trstmh/trad084. Trans R Soc Trop Med Hyg. 2024. PMID: 38048279
RESULTS: Nine RCTs were included and analysed. Compared with controls, lamivudine significantly decreased HBsAb seronegativity in the newborn within 24 h after birth (indicating the foetal immune response to HBV). Similar results were noted in infants within 6-7 months aft …
RESULTS: Nine RCTs were included and analysed. Compared with controls, lamivudine significantly decreased HBsAb seronegativity in the …
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study.
Figueroa MI, Brites C, Cecchini D, Ramalho A, Francos JL, Lacerda M, Rolon MJ, Madruga JV, Sprinz E, Souza TNL, Parenti P, Converso D, Mernies G, Sued O, Cahn P; DOLCE study group. Figueroa MI, et al. Clin Infect Dis. 2026 Feb 9;82(1):122-131. doi: 10.1093/cid/ciaf415. Clin Infect Dis. 2026. PMID: 40874763 Clinical Trial.
BACKGROUND: Dolutegravir (DTG)/lamivudine dual therapy (DT) has demonstrated noninferiority to triple therapy (TT) in the GEMINI trials. ...This trial evaluated the antiviral activity of dolutegravir/lamivudine among antiretroviral therapy (ART)-naive patients with …
BACKGROUND: Dolutegravir (DTG)/lamivudine dual therapy (DT) has demonstrated noninferiority to triple therapy (TT) in the GEMINI tria …
Oral lamivudine in diabetic macular edema: A randomized, double-blind, placebo-controlled clinical trial.
Pereira F, Magagnoli J, Ambati M, Fernandes de Oliveira T, Estevão de Oliveira JA, Pesquero VO, Ribeiro LZ, Kondo Kuroiwa DA, Malerbi FK, Dib SA, Moraes NB, Farah ME, Rodrigues EB, Ambati J. Pereira F, et al. Med. 2025 Sep 12;6(9):100747. doi: 10.1016/j.medj.2025.100747. Epub 2025 May 27. Med. 2025. PMID: 40436012 Clinical Trial.

FINDINGS: At 4 weeks, BCVA improved 9.8 letters with lamivudine and decreased 1.8 letters with placebo (p < 0.001). At 8 weeks, BCVA improved 16.9 letters with lamivudine and bevacizumab and 5.3 letters with placebo and bevacizumab (p < 0.001). Lamivudine

…

FINDINGS: At 4 weeks, BCVA improved 9.8 letters with lamivudine and decreased 1.8 letters with placebo (p < 0.001). At 8 weeks, BC

…
Lamivudine prevents reactivation of hepatitis B and reduces mortality in immunosuppressed patients: systematic review and meta-analysis.
Katz LH, Fraser A, Gafter-Gvili A, Leibovici L, Tur-Kaspa R. Katz LH, et al. J Viral Hepat. 2008 Feb;15(2):89-102. doi: 10.1111/j.1365-2893.2007.00902.x. J Viral Hepat. 2008. PMID: 18184191
Lamivudine significantly reduced HBV-related mortality, and discontinuations or disruptions of the immunosuppressive treatment. No adverse effects of lamivudine were recorded, and resistance to lamivudine occurred in low rates. We demonstrated a clear benefit …
Lamivudine significantly reduced HBV-related mortality, and discontinuations or disruptions of the immunosuppressive treatment. No ad …
1,362 results